PT - JOURNAL ARTICLE ED - , TI - ▼Romosozumab for osteoporosis AID - 10.1136/dtb.2021.000027 DP - 2021 Aug 19 TA - Drug and Therapeutics Bulletin PG - dtb-2021-000027 4099 - http://dtb.bmj.com/content/early/2021/08/18/dtb.2021.000027.short 4100 - http://dtb.bmj.com/content/early/2021/08/18/dtb.2021.000027.full AB - Generic name: RomosozumabBrand name: EvenityFormulation: 105 mg solution for injection in a pre-filled penMarket Authorisation holder: UCB Pharma LimitedIndication: treatment of severe osteoporosis in postmenopausal women at high risk of fractureDose: 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once a month for 12 months. It is recommended that patients begin antiresorptive therapy after completing treatment with romosozumab.Cost: £427.75 for two pre-filled pens each containing 105 mg romosozumabClassification: Prescription only medicine (POM) subject to additional monitoring (▼)